ISSN 3080-7670(Print)
ISSN 3080-7689(Online)
版权信息 · Copyright

     加入编委 / 副主编 / 同行评议专家
ISSN 3080-7670(Print)
ISSN 3080-7689(Online)

CODEN:ZYYYBQ
国际标准连续出版物标识符·全球唯一标识符
分配机构:美国化学文摘社
(CAS)
DOI前缀:
https://doi.org/10.66106/zyyybq
国图集团 CIBTC
进口备案刊号:G015Z111

索引 / 检索 / 存档(Global Indexing)
本刊入选以下全球权威数据库,致力于研究成果的全球化无障碍传播。

CNKI(中国知网,申请中)
CNKI Open(中国知网·开放平台,申请中)
Wanfang Data(万方数据,中国,更新中)
CQVIP(维普期刊网,中国)
CQVIP(中文期刊服务平台,中国)
RCCSE(中国学术期刊目录,武汉大学)
CJWK(长江文库,中国)
BOOKAN(博看,中国)
591adb(中邮阅读·万章期刊,中国)
Baidu Scholar(百度学术,中国)
Baidu Baike(百度百科,中国)
ICI(哥白尼期刊数据库,波兰)
EuroPub(欧洲学术出版数据库,英国)
MDPI scilit(科学与学术数据库,瑞士)
Crossref(交叉引用,美国)
Semantic Scholar(语义学术,美国)
OpenAlex(全球开源学术平台,加拿大)
ACADEMIA.EDU(学术界,美国)
OUCI(开放乌克兰科学,乌克兰)
WorldCat(世界编目数据库,美国)
Scite(智能引文分析数据库,美国)
The Lens(透镜学术,澳大利亚)
OpenAIRE(开放学术发现门户,欧洲)
Google Scholar(谷歌学术,美国)
DOI(数字对象唯一标识符,英国)
Portico(数字存储库,美国)
J-Gate(开放获取期刊门户,印度)
ResearchGate(研究之门,德国)
Research Commons(科睿唯安,美国)
Socolar(开放获取资源检索,中国,更新中)
Sci Online(科学在线,中国澳门)
OALib(开放存取资源图书馆,美国)
EZB(电子期刊图书馆,德国,申请中)
Road(开放科学学术资源,法国)
ISI(国际科学索引平台,阿联酋迪拜)
ASCI(亚洲科学引文索引,美国)
ESJI(欧亚科学期刊索引,哈萨克斯坦)
ResearchBib(研究者索引,日本)
SPI-Hub™(范德比尔特大学,美国)
SJIF(科学期刊影响因子,印度)
RJIF(研究期刊影响因子)
COSMOS(期刊评价指标,印度)
LivRe!(开放期刊门户,巴西)
KIND CONGRESS(阿塞拜疆)
Journament(质量评估与索引)
IP Indexing(ip索引)
Magzter(跨平台数字期刊,美国)
SlideShare(知识共享平台,美国)
SCRIBD(在线图书馆,美国)
Yahoo! Search(雅虎,美国)
Microsoft Bing(微软学术,美国)
LibKey(学术文献快捷获取工具)
R Discovery(研究者发现平台,印度)
Enterscholar(恩特学术)

规划申请

SinoMed 中国生物医学文献服务系统
EBSCO 学术文献数据库(美国)

CABI 国际农业与生物科学中心(英国)
OAJ 全球OA期刊索引(中国)
DOAJ 开放获取期刊目录(瑞典)
PubMed 医学文摘数据库(美国)
PubMed Central 医学全文数据(美国)
Scopus 爱思唯尔·斯高帕斯(荷兰)
EMBASE 爱思唯尔·医学文摘(荷兰)
ProQuest 科睿唯安(美国)
Research4Life 世界卫生组织数据库

Editing and Publishing
Quest Press Limited
Address
Unit D, 7th Floor, No. 19, Rua de Pa̍k-chiông Vai, Macau
Telephone
+853 6881 9699
Email
QuestPress@hotmail.com
Web site
https://zyyyj.scionline2025.com

  往期阅览 · All Issues-> 2025年 · 2025  
中医药研究与应用,2025年,第1卷,第2期,第56-60页,pISSN 3080-7670、eISSN 3080-7689 发布者:Quest Press 发布日期:2026/1/22
Open Access 浏览223次

 

中药调控PI3K/AKT信号通路干预黑色素瘤的研究进展


蒲一萍,刘春涛,张春霞,李建刚

定西市妇幼保健院,甘肃定西,743000

摘要:恶性黑色素瘤(Malignant melanoma,MM)是一种源于黑色素细胞异常生长的恶性肿瘤,有高转移性和高致死性,后者占皮肤癌相关死亡比例>80%。PI3K/AKT信号通路的异常激活会促进MM的发生,在MM病理进程中具有重要意义。目前研究发现,多种中药对恶性黑色素瘤具有很好的效果。本文基于PI3K/AKT信号通路系统总结中药复方及注射液和单体干预MM的作用机制,发现中药复方及注射液(归芪白术方、复方苦参注射液、四君子汤)和中药单体萜类(人参皂甙、三七总苷、α-常春藤皂苷等)、酚类(白藜芦醇、姜黄素、山萘酚等)、黄酮类(半枝莲总黄酮、新藤黄酸、淫羊藿苷等)等均可通过抑制PI3K/AKT信号通路的关键分子,从而抑制MM。基于此,本文总结了中药单体及复方干预PI3K/AKT信号通路干预黑色素瘤的研究进展,以期为中药防治恶性黑色素瘤的临床应用及新药研发提供思路。

关健词:中药;恶性黑色素瘤;PI3K/AKT信号通路;作用机制
Research progress of traditional Chinese medicine in regulatingPI3K/AKT signaling pathway to interfere with malignant melanoma

Yiping Pu,Chuntao Liu,Chunxia Zhang,Jiangang Li

Dingxi Maternal and Child Health Care Hospital, Dingxi Gansu 743099, China

Abstract:Malignant melanoma (MM) is a kind of malignant tumour originating from the abnormal growth of melanocytes, It has a high degree of metastasis and lethality, with the latter accounting for more than 80% of skin cancer-related deaths. Abnormal activation of PI3K/AKT signaling pathway can promote the occurrence of MM,which has important significance in the pathological process of MM. Current research has found that A variety of traditional Chinese medicine has a good effect on malignant melanoma.In this paper, we summarise the mechanism of action of Chinese herbal compounds and monomers intervening in MM based on the PI3K/AKT signalling pathway, and find that Chinese herbal compounds (Guiqi Baijutsu Formula, Compound Bitter Ginseng Injection, Sijunzi Tang) as well as Chinese herbal monomers of terpenoids(ginsenoside, total Panax ginseng glycosides, α-Ivy saponins, etc.),phenolics(resveratrol,curcumin,sennosides,etc.),flavonoids (hemicarpene total flavonoids, neo garcinia cambogia acid, epimedium glycosides, etc.) etc. can all reduce MM by affecting the PI3K/AKT signalling pathway. Based on this, this paper summarized the research progress of TCM monomer and compound intervention of PI3K/AKT signaling pathway in the intervention of melanoma, in order to provide ideas for the clinical application of TCM in the prevention and treatment of malignant melanoma and the development of new drugs.


Keywords : traditional Chinese medicine; malignant melanoma; PI3K/AKT signaling pathway; mechanism of action


参考文献
[1] Vincenzo Papa,Federica Li Pomi,Francesco Borgia,et al. Alarmins in cutaneous malignant melanoma: An updated overview of emerging evidence on their pathogenetic, diagnostic, prognostic, and therapeutic role[J]. J Dermatol,2024,51(7):927-938.
[2] Sung H,Ferlay J,Siegel RL,et al. Global Cancer Statistics 2020:GLOBOCAN Estimates of Incidence andMortality Worldwide for 36Cancers in 185 Countries[J]. CA Cancer J Clin2021,71:209–249.
[3] De Pinto G,Mignozzi S,La Vecchia C F EC .Global trends in cutaneous malignant melanoma incidence and mortality[J].Melanoma research,2024,34(3):265-275.
[4] 艾尔肯·买提沙衣木,玉素甫江·买买提明,艾克拜尔·买提努尔.基于信号通路中医药治疗黑色素瘤的研究进展[J].新疆医学,2021,51(12):1406-1409+1400.
[5] 邓福临,郭宇晗,吕大伦.黑色素瘤的中药治疗研究进展[J].齐齐哈尔医学院学报,2022,43(13):1259-1264.
[6] LAWRENCE M S,STOJANOV P,MERMELC H,et al. Discovery and saturation analysis of cancer genes across 21 tumour types [J]. Nature,2014,505(7484):495-501.
[7] DENLEY A , KANG S , KARST U , et al. Oncogenic signaling of class I PI3K isoforms [J]. Oncogene,2008,27(18):2561-2574.
[8] BILANGES B , POSOR Y ,VANHAESEBROECK B. PI3K isoforms in cellsignalling and vesicle trafficking [J]. Nature Reviews Molecular Cell Biology,2019,20(9):515-34.
[9] FRUMAN D A,CHIU H,HOPKINS B D,et al. The PI3K Pathway in Human Disease [J].Cell,2017,170(4):605-635.
论文收录证明 / 文献检索报告
Document Retrieval Certificate / Proof of Publication Indexing
作者贡献声明 / 贡献确认书
Author Contribution Statement / Certificate of Authorship Contribution
同行评审报告 / 评审意见
Peer Review Report / Peer Review Comments
利益冲突
Conflict of Interest
作者声明不存在任何利益冲突。
The author declares no conflict of interest.
版权声明
Copyright Statement
本文采用知识共享“署名 4.0 国际”许可 (CC BY 4.0) 进行许可。许可协议详情请访问: https://creativecommons.org/licenses/by/4.0/。
This article is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). For details of the license, please visit:https://creativecommons.org/licenses/by/4.0/.

 
Peer Review
同行评审
Editorial Services
编辑服务
Research Ethics Policy
研究伦理政策
Contributorship & Authorship
贡献者与署名
Quest Press / Macau Sino-Foreign Medical Publishing Ltd.
关于 Quest Press / Macau Sino-Foreign Medical Publishing Ltd.
Global Indexing
全球索引
Copyright Licensing
版权许可
Data Sharing Policy
数据共享政策
Appeal/Correction/Retraction
申诉/更正/撤回
Online Submission
线上投稿
To the Librarian
致图书馆员
Open Access Statement
开放获取声明
Misconduct Handling Policy
处理不端行为政策
Content Licensing
内容许可
Guidelines for Reviewers
审稿人指南
Quality Control Mechanism
质量把控机制
Academic Misconduct Screening Policy
学术不端筛查政策
Advertising Policy
广告政策
Article Processing Charge (APC)
文章处理费
Publication Ethics Policy
出版伦理政策
Joining the Editorial Board, Associate Editors, Peer Reviewers, and Editor-in-Chief
加入编委、副主编、同行评审专家及主编
Quest Press
Bridging Research to a Global Stage.
academia
© 2025-2026 Quest Press Ltd.
Address: Unit D, 7th Floor, No. 19, Rua de Pa̍k-chiông Vai, Macau
Tel: +853 6881 9699 / Email: QuestPress@hotmail.com
The QUEST PRESS publishes articles under the following open access license.
Quest Press
is a member of the following organizations.